AI Bias Analysis
4 models · Takes ~15 seconds
A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.
Source
Stat News
Opens original article in a new tab
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
What the FDA has lost, why hantavirus isn't the next pandemic, and more health news from Morning Rounds
In this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water as an ALS treatment.
The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.
